Creative Planning Increases Position in Pediatrix Medical Group, Inc. (NYSE:MD)

Creative Planning grew its stake in Pediatrix Medical Group, Inc. (NYSE:MD) by 48.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 30,662 shares of the company’s stock after acquiring an additional 9,991 shares during the quarter. Creative Planning’s holdings in Pediatrix Medical Group were worth $355,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in Pediatrix Medical Group by 1.6% during the 1st quarter. Vanguard Group Inc. now owns 10,557,572 shares of the company’s stock valued at $105,892,000 after buying an additional 164,333 shares in the last quarter. Rubric Capital Management LP increased its position in Pediatrix Medical Group by 797.0% during the 2nd quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company’s stock valued at $61,532,000 after buying an additional 7,241,400 shares in the last quarter. Boston Partners increased its position in Pediatrix Medical Group by 34.0% during the 1st quarter. Boston Partners now owns 1,786,434 shares of the company’s stock valued at $17,702,000 after buying an additional 453,254 shares in the last quarter. Dana Investment Advisors Inc. increased its position in Pediatrix Medical Group by 80.3% during the 2nd quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company’s stock valued at $7,725,000 after buying an additional 455,785 shares in the last quarter. Finally, Brandes Investment Partners LP increased its position in Pediatrix Medical Group by 12.8% during the 2nd quarter. Brandes Investment Partners LP now owns 735,068 shares of the company’s stock valued at $5,438,000 after buying an additional 83,588 shares in the last quarter. 97.71% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Pediatrix Medical Group

In related news, Director Laura A. Linynsky sold 7,000 shares of the stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total value of $78,120.00. Following the completion of the sale, the director now owns 30,805 shares of the company’s stock, valued at approximately $343,783.80. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Pediatrix Medical Group news, CFO C Marc Richards sold 17,438 shares of the firm’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $10.08, for a total transaction of $175,775.04. Following the completion of the sale, the chief financial officer now owns 175,347 shares of the company’s stock, valued at $1,767,497.76. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Laura A. Linynsky sold 7,000 shares of the firm’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total value of $78,120.00. Following the sale, the director now directly owns 30,805 shares of the company’s stock, valued at approximately $343,783.80. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 35,538 shares of company stock valued at $373,664. 2.00% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Jefferies Financial Group increased their price objective on Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday. UBS Group increased their price objective on Pediatrix Medical Group from $10.50 to $16.50 and gave the company a “neutral” rating in a report on Tuesday. StockNews.com raised Pediatrix Medical Group from a “sell” rating to a “hold” rating in a report on Wednesday, August 7th. Truist Financial increased their price objective on Pediatrix Medical Group from $13.00 to $16.00 and gave the company a “hold” rating in a report on Monday, November 4th. Finally, Deutsche Bank Aktiengesellschaft upped their target price on Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a research note on Monday, November 4th. Five research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $16.10.

Pediatrix Medical Group Price Performance

Shares of Pediatrix Medical Group stock opened at $15.76 on Friday. The business has a 50 day simple moving average of $12.08 and a two-hundred day simple moving average of $9.64. Pediatrix Medical Group, Inc. has a 12 month low of $6.62 and a 12 month high of $16.41. The stock has a market capitalization of $1.35 billion, a P/E ratio of -5.15, a PEG ratio of 2.38 and a beta of 1.55. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.42 and a quick ratio of 1.38.

Pediatrix Medical Group (NYSE:MD) last announced its earnings results on Friday, November 1st. The company reported $0.44 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.07. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The business had revenue of $511.20 million during the quarter, compared to analysts’ expectations of $498.87 million. During the same quarter in the prior year, the firm earned $0.29 earnings per share. The business’s revenue was up .9% compared to the same quarter last year. As a group, analysts predict that Pediatrix Medical Group, Inc. will post 1.21 EPS for the current fiscal year.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.